The trial is a phase 4, open-label, multicentre clinical trial with healthy subjects who have been vaccinated with IPV-Al AJV at 2, 4, 6 and 15 18 months of age in previous trials. Levels of antibodies against poliovirus types 1, 2 and 3 after immunisation with IPV Al AJV will be measured in the trial subjects at the age of 4 years. An additional IPV-Al AJV dose (investigational vaccine) will be administered and the booster response to IPV-Al AJV will be investigated one month after administration.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
163
adjuvanted reduced dose inactivated polio vaccine
Cevaxim
Panama City, Panama
Seroprotection (titer ≥8) against poliovirus types 1, 2 and 3
Individual serum titers against poliovirus types 1, 2 and three will be measured in collected serum samples
Time frame: One month after administration of an additional dose of IPV-Al AJV
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.